Early Detection and Referral for Autism and Neurodevelopmental Disorders at the Maternal and Child Protection Services

Launched by CENTRE HOSPITALIER INTERCOMMUNAL CRETEIL · Apr 3, 2023

Keywords

ClinConnect Summary

This clinical trial is designed to explore two different ways of screening infants for early signs of Autism Spectrum Disorder and other neurodevelopmental disorders. The goal is to identify these conditions as early as possible so that children can receive the care they need, which can help improve their development and overall outcomes. The study will be conducted at Maternal and Child Protection Services and is not yet recruiting participants.

To participate, infants need to be between 4 and 9 months old and must be receiving their fourth and ninth-month vaccinations at the participating services. Parents will need to provide consent for their child's involvement and agree to keep in touch with the study team until the child is 36 months old. It’s also important that at least one parent can speak French or has a French-speaking relative. Infants with serious neurological issues cannot participate, and parents must be willing to take part in the study. If you have a child that fits these criteria, this study could be a valuable opportunity to help with early detection and support for autism and related disorders.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria:in
• • Infants between 4 and 9 months of age followed up in the participating Maternal and Child Protection Services for the fourth and ninth-month mandatory vaccinations
• • Availability of a personnel telephone for at least one parent
• • Information to the parents for data collection and the active follow-up of the child until 36 months and express consent to participate in the research
• • Affiliation to a social security system or benefiting from the Medical assistance of the state
• • Mastery of a minimum of French according to the principal investigator or the presence of a French-speaking relative
• Exclusion Criteria:
• • Infant with a severe neurological pathology such as encephalopathy
• • Refusal to participate in the study